You are here

Moderna says experimental Covid vaccine 94.5% effective

Its interim analysis is based on 95 infections among trial participants who received either a placebo or the vaccine

BT_20201117_NAHVAC17_4329498.jpg
A key advantage of Moderna's vaccine is that it does not need ultra-cold storage like Pfizer's, making it easier to distribute. It is stable at standard refrigerator temperatures of 2-8 deg Celsius for 30 days.

Massachusetts

MODERNA Inc said on Monday its experimental vaccine was 94.5 per cent effective in preventing Covid-19 based on interim data from a late-stage clinical trial, becoming the second US company in a week to report results that far exceed expectations.

Together with Pfizer...

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes